Illumina, Inc. (NASDAQ:ILMN) Position Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its holdings in Illumina, Inc. (NASDAQ:ILMNFree Report) by 0.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 883,900 shares of the life sciences company’s stock after purchasing an additional 6,970 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.56% of Illumina worth $121,342,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Acadian Asset Management LLC raised its holdings in shares of Illumina by 312.5% during the first quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company’s stock worth $702,000 after acquiring an additional 1,525 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Illumina by 3.1% during the first quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company’s stock worth $82,853,000 after acquiring an additional 7,114 shares in the last quarter. Dakota Wealth Management raised its holdings in shares of Illumina by 13.8% during the first quarter. Dakota Wealth Management now owns 826 shares of the life sciences company’s stock worth $288,000 after acquiring an additional 100 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Illumina by 16.9% during the first quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company’s stock worth $281,000 after acquiring an additional 116 shares in the last quarter. Finally, Baird Financial Group Inc. raised its holdings in shares of Illumina by 10.2% during the first quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company’s stock worth $17,108,000 after acquiring an additional 4,548 shares in the last quarter. Hedge funds and other institutional investors own 92.17% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent research reports. Wolfe Research initiated coverage on Illumina in a report on Wednesday, December 13th. They set an “outperform” rating and a $175.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and set a $258.00 target price on shares of Illumina in a report on Friday. Stephens initiated coverage on Illumina in a report on Thursday, December 14th. They set an “overweight” rating and a $170.00 target price on the stock. Piper Sandler cut their target price on Illumina from $200.00 to $190.00 and set an “overweight” rating on the stock in a report on Monday, November 13th. Finally, Bank of America lowered Illumina from a “neutral” rating to an “underperform” rating and cut their target price for the company from $140.00 to $100.00 in a report on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $166.95.

Get Our Latest Research Report on Illumina

Illumina Trading Down 3.8 %

Shares of ILMN opened at $137.84 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.28 and a current ratio of 1.69. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $238.55. The company has a 50-day moving average price of $135.24 and a two-hundred day moving average price of $138.32.

Illumina (NASDAQ:ILMNGet Free Report) last announced its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.15%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.14 earnings per share. On average, research analysts predict that Illumina, Inc. will post 1.04 EPS for the current year.

Illumina Profile

(Free Report)

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Read More

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.